$HSCSW

HeartSciences Inc. (HSCS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 PRESS RELEASE Fortitude Appoints Jaime Leverton as Chief Executive Officer Former Hut 8 CEO to Lead Fortitude as the Zcash-Focused, Vertically-Integrated Mining Platform Advances Toward the Public Markets; Andrea Childs to Transition to Chief Operating Officer Fairpo

Fortitude, a Zcash miner owned by Digital Currency Group, appointed former Hut 8 CEO Jaime Leverton as CEO ahead of its Nasdaq listing via a merger with HeartSciences (HSCS). The combined company, valued at $400M+, will trade as 'TUDE'. Fortitude mined 28% of ZEC in H1 2026, reporting $20.9M Q2 revenue.

HeartSciences Inc. (HSCS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 HeartSciences Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update Proposed business combination with Fortitude, a vertically-integrated digital asset mining platform anchored in Zcash, continues to progress, with closing expected in Q4 ca

HeartSciences (HSCS) reported a wider FQ1 2027 loss of $3.2M, up from $2.1M a year ago. The company is advancing a merger with Fortitude Mining, expected to close in Q4 2026. MyoVista Insights, its ECG platform, gained commercial traction with U.S. agreements and a European clinical program. HSCS raised $2.2M post-quarter. The stock is down 6.07% at $3.32.

HeartSciences Inc. reported Q1 2027 fiscal results with revenue of $2.1K, a net loss of $3.17M, and EPS of $(0.86). Revenue was flat year-over-year, while the net loss widened from $(2.06M). The company launched MyoVista Insights™ upgrades and an AI marketplace, signed commercial agreements, and submitted a 510(k) for the wavECG device.

HeartSciences Inc. (HSCS) reported a net loss of $3.17M for Q2 2026, wider than the prior-year loss, with revenue at $2,100. Cash fell to $29,906, and stockholders' equity deficit reached $2.03M, prompting a Nasdaq compliance notice. Management expressed doubt about the company's going concern status and is pursuing a merger and capital raises.

Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.

HeartSciences Inc. (HSCS) received a $1 million investment from Fortitude Mining Holdings at a 22% premium, buying 411,522 shares at $2.43 each. Fortitude now owns 9.4% of HSCS stock. The deal strengthens HSCS's balance sheet ahead of a planned merger in late 2026. HSCS stock is up 10.33% to $2.35.

HeartSciences Inc. (HSCS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement On August 12, 2026, HeartSciences Inc. (the “ Company ” or “ HeartSciences ”) sold and issued to Fortitude Mining Holdings, Inc., a Delaware corporation (“ Fortitude ”), an aggregate of 411,522 shares (the “ Shares ”) of Heart

HeartSciences Inc. (HSCS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results ● Company believes proposed Fortitude Mining Holdings business combination represents a signifi